News and Announcements
Collaborate Secures Underwriting For $1.26 Million Of Listed Options
- Published February 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Existing Collaborate shareholders underwrite $1.26 million of listed CL8O options.
- $500,000 of funds to be advanced immediately to provide funding for operations.
- Anticipated drawdowns via the Flexible Equity Facility halted in preference to raising funds via exercise of options.
Collaborate Corporation Limited (ASX:CL8 or the Company) is pleased to announce that the Company has entered into agreements with existing sophisticated investors (Underwriters) to underwrite the exercise of 63 million of the Company’s quoted options (ASX:CL8O) (Underwriting Agreements), representing approximately 37% of CL8O options on issue. Originally targeting $1 million of underwriting, the Company is very pleased with the overapplication and support shown by the underwriters.
The Underwriting Agreements will guarantee that the Company receives $1.26 million (Underwritten Amounts) before costs and also grants the Underwriters a first right of refusal on any unexercised CL8O options. The underwriting places the Company in a strong financial position to drive growth of the peer-to-peer marketplaces, support the launch of Mobilise, pursue investment opportunities that align with the Company’s peer-to-peer strategy as well as supplement working capital.
To view the full ASX Announcement, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
